North American Molecular Diagnostics Market

Molecular diagnostics is the fastest-growing segment in the IVD market driven by infectious diseases and oncology. The market is expected to grow due an increasing pool in the aging population across the globe, a concurrent augmentation in the prevalence of chronic diseases, and the need for the diagnosis of such diseases at early stages. The market is driven by increasing awareness and acceptance of personalized medicines, advancements in molecular techniques, inherited disease testing, and prenatal testing. However, persistent reimbursement issues and delays in the approval of molecular diagnostic tests are expected to curb the growth of this market.

The Centers for Medicare & Medicaid Services (CMS) has estimated that healthcare spending in the U.S. is expected to grow from $2.7 trillion in 2011 to about $4.6 trillion in 2017, at a CAGR of 6.8% for the same period. Similarly, in emerging countries, awareness and an increasing middle-class population, with a more disposable income to spend on healthcare, will be a driving force for the growth of this market.

The report ‘North American Molecular Diagnostics Market forecast for 2018’ analyzes the market by segments such as instruments and reagents.

The Americas commanded the largest share of 42% in the global molecular diagnostics market with $2066.7 million in 2013, and is expected to reach $3221.4 million by 2018, at a CAGR of 9.7% from 2013 to 2018.

The U.S. commanded the largest share of 89% in the North American molecular diagnostics IVD market with $1837.7 million in 2013, and is expected to reach $2859.2 million by 2018, at a CAGR of 9.6% from 2013 to 2018.

The report also provides an extensive competitive landscaping of companies operating in this market. The major players are Roche Diagnostics (Switzerland), Novartis (Switzerland), Gen-probe (U.S.), Qiagen (The Netherlands), and Abbott Diagnostics (U.S.) Segment and country specific company shares, news & deals, mergers and acquisitions, segment specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.

Customization Options

Along with the market data, you can also customize MMM assessments that meet your company’s specific needs. Customize to get comprehensive industry standard and deep dive analysis of the following parameters:

Opportunity Analysis

• Unmet needs, revenue pockets, and potential areas for expansion

MDx Business Model

• Comprehensive review of key component providers, assay providers, sole service providers, and complete solution providers

Current and Emerging Products

• Analysis of current and emerging molecular diagnostics and immunodiagnostic tests
• Review of current instrumentation technologies

Pricing Trends

• Pricing trend of new high value* MDx tests

Product Analysis

• Usage pattern (in-depth trend analysis) of products (segment wise)
• Product matrix which gives a detailed comparison of product portfolio of each company mapped at country and sub-segment level
• End-user adoption rate analysis of the products (segment wise and country wise)
• Comprehensive coverage of product approvals, pipeline products, and product recalls

Brand/Product Perception Matrix

• Comprehensive study of customers perception and behavior through our inbuilt social connect tool checking the virility and tonality of blogs
• Analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)

Alternative Products: Impact analysis

MMM’s healthcare decision making quadrant is an innovative and useful quadrant for vendors who wish to analyze the potential growth markets based on parameters like patient dynamics (patient pool, epidemiology of disease, preference towards surgeries/alternative therapies) and macroeconomic indicators (number of hospitals and orthopedic clinics, reimbursement scenario, diagnosis rate, treatment rate and healthcare expenditure).

1 Introduction
1.1 Objective of the study
1.2 Market Definitions
1.3 Market Segmentation & Aspects Covered
1.4 Research Methodology
1.4.1 Assumptions (Market Size, Forecast, etc)

2 Executive Summary
 

3 Market Overview
 

4 Molecular Diagnostics-North America, by Applications
4.1 Split by Geography
4.1 Molecular Diagnostics-USA by Applications
4.1 Molecular Diagnostics-Canada by Applications
4.1 Molecular Diagnostics-Mexico by Applications
4.2 Molecular Diagnostics-Genetic Testing-North America
4.2.1 Molecular Diagnostics-Genetic Testing-North America, by Geographies
4.2.1.1 Molecular Diagnostics-Genetic Testing-USA
4.2.1.2 Molecular Diagnostics-Genetic Testing-Canada
4.3 Molecular Diagnostics-Microbiology-North America
4.3.1 Molecular Diagnostics-Microbiology-North America, by Geographies
4.3.1.1 Molecular Diagnostics-Microbiology-USA
4.3.1.2 Molecular Diagnostics-Microbiology-Canada
4.4 Molecular Diagnostics-Chlamydia trachomatis/ Neisseria gonorrhoeae-North America
4.4.1 Molecular Diagnostics-Chlamydia trachomatis/ Neisseria gonorrhoeae-North America, by Geographies
4.4.1.1 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.4.1.2 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.4.1.3 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.4.1.4 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.4.1.5 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.4.1.6 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
4.5 Molecular Diagnostics-Hepatitis B-North America
4.5.1 Molecular Diagnostics-Hepatitis B-North America, by Geographies
4.5.1.1 Molecular Diagnostics-USA-Hepatitis B
4.5.1.2 Molecular Diagnostics-USA-Hepatitis B
4.5.1.3 Molecular Diagnostics-USA-Hepatitis B
4.5.1.4 Molecular Diagnostics-Canada-Hepatitis B
4.5.1.5 Molecular Diagnostics-Canada-Hepatitis B
4.5.1.6 Molecular Diagnostics-Canada-Hepatitis B
4.6 Molecular Diagnostics--North America
4.6.1 Molecular Diagnostics--North America, by Geographies
4.6.1.1 Molecular Diagnostics--USA
4.6.1.2 Molecular Diagnostics--Canada
4.7 Molecular Diagnostics-Breast Cancer-North America
4.7.1 Molecular Diagnostics-Breast Cancer-North America, by Geographies
4.7.1.1 Molecular Diagnostics-USA-Breast Cancer
4.7.1.2 Molecular Diagnostics-USA-Breast Cancer
4.7.1.3 Molecular Diagnostics-USA-Breast Cancer
4.7.1.4 Molecular Diagnostics-Canada-Breast Cancer
4.7.1.5 Molecular Diagnostics-Canada-Breast Cancer
4.7.1.6 Molecular Diagnostics-Canada-Breast Cancer
4.8 Molecular Diagnostics-Human Papillomavirus-North America
4.8.1 Molecular Diagnostics-Human Papillomavirus-North America, by Geographies
4.8.1.1 Molecular Diagnostics-USA-Human Papillomavirus
4.8.1.2 Molecular Diagnostics-USA-Human Papillomavirus
4.8.1.3 Molecular Diagnostics-USA-Human Papillomavirus
4.8.1.4 Molecular Diagnostics-Canada-Human Papillomavirus
4.8.1.5 Molecular Diagnostics-Canada-Human Papillomavirus
4.8.1.6 Molecular Diagnostics-Canada-Human Papillomavirus
4.9 Molecular Diagnostics-HIV/AIDS-North America
4.9.1 Molecular Diagnostics-HIV/AIDS-North America, by Geographies
4.9.1.1 Molecular Diagnostics-USA-HIV/AIDS
4.9.1.2 Molecular Diagnostics-USA-HIV/AIDS
4.9.1.3 Molecular Diagnostics-USA-HIV/AIDS
4.9.1.4 Molecular Diagnostics-Canada-HIV/AIDS
4.9.1.5 Molecular Diagnostics-Canada-HIV/AIDS
4.9.1.6 Molecular Diagnostics-Canada-HIV/AIDS
4.10 Molecular Diagnostics-Tuberculosis-North America
4.10.1 Molecular Diagnostics-Tuberculosis-North America, by Geographies
4.10.1.1 Molecular Diagnostics-USA-Tuberculosis
4.10.1.2 Molecular Diagnostics-USA-Tuberculosis
4.10.1.3 Molecular Diagnostics-USA-Tuberculosis
4.10.1.4 Molecular Diagnostics-Canada-Tuberculosis
4.10.1.5 Molecular Diagnostics-Canada-Tuberculosis
4.10.1.6 Molecular Diagnostics-Canada-Tuberculosis
4.11 Molecular Diagnostics-Hepatitis C-North America
4.11.1 Molecular Diagnostics-Hepatitis C-North America, by Geographies
4.11.1.1 Molecular Diagnostics-USA-Hepatitis C
4.11.1.2 Molecular Diagnostics-USA-Hepatitis C
4.11.1.3 Molecular Diagnostics-USA-Hepatitis C
4.11.1.4 Molecular Diagnostics-Canada-Hepatitis C
4.11.1.5 Molecular Diagnostics-Canada-Hepatitis C
4.11.1.6 Molecular Diagnostics-Canada-Hepatitis C
4.12 Molecular Diagnostics-Methicillin-resistant Staphylococcus aureus (MRSA)-North America
4.12.1 Molecular Diagnostics-Methicillin-resistant Staphylococcus aureus (MRSA)-North America, by Geographies
4.12.1.1 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
4.12.1.2 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
4.12.1.3 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
4.12.1.4 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
4.12.1.5 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
4.12.1.6 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
4.13 Molecular Diagnostics-Colorectal Cancer-North America
4.13.1 Molecular Diagnostics-Colorectal Cancer-North America, by Geographies
4.13.1.1 Molecular Diagnostics-USA-Colorectal Cancer
4.13.1.2 Molecular Diagnostics-USA-Colorectal Cancer
4.13.1.3 Molecular Diagnostics-USA-Colorectal Cancer
4.13.1.4 Molecular Diagnostics-Canada-Colorectal Cancer
4.13.1.5 Molecular Diagnostics-Canada-Colorectal Cancer
4.13.1.6 Molecular Diagnostics-Canada-Colorectal Cancer
4.14 Molecular Diagnostics-Prostate Cancer-North America
4.14.1 Molecular Diagnostics-Prostate Cancer-North America, by Geographies
4.14.1.1 Molecular Diagnostics-USA-Prostate Cancer
4.14.1.2 Molecular Diagnostics-USA-Prostate Cancer
4.14.1.3 Molecular Diagnostics-USA-Prostate Cancer
4.14.1.4 Molecular Diagnostics-Canada-Prostate Cancer
4.14.1.5 Molecular Diagnostics-Canada-Prostate Cancer
4.14.1.6 Molecular Diagnostics-Canada-Prostate Cancer
 

5 Molecular Diagnostics-North America, by Endusers
5.1 Split by Geography
5.2 Molecular Diagnostics-USA by Endusers
5.1 Molecular Diagnostics-Canada by Endusers
5.1 Molecular Diagnostics-Mexico by Endusers
5.2 Molecular Diagnostics-North America-Hospitals
5.2.1 Molecular Diagnostics-North America-Hospitals, by Geographies
5.2.1.1 Molecular Diagnostics-USA-Hospitals
5.2.1.2 Molecular Diagnostics-Canada-Hospitals
5.3 Molecular Diagnostics-North America-Medical & Diagnostic Laboratories
5.3.1 Molecular Diagnostics-North America-Medical & Diagnostic Laboratories, by Geographies
5.3.1.1 Molecular Diagnostics-USA-Medical & Diagnostic Laboratories
5.3.1.2 Molecular Diagnostics-Canada-Medical & Diagnostic Laboratories
5.4 Molecular Diagnostics--North America
5.4.1 Molecular Diagnostics--North America, by Geographies
5.4.1.1 Molecular Diagnostics--USA
5.4.1.2 Molecular Diagnostics--Canada
 

6 Molecular Diagnostics-North America, by Technologies
6.1 Split by Geography
6.3 Molecular Diagnostics-USA by Technologies
6.1 Molecular Diagnostics-Canada by Technologies
6.1 Molecular Diagnostics-Mexico by Technologies
6.2 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-North America
6.2.1 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-North America, by Geographies
6.2.1.1 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-USA
6.2.1.2 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-Canada
6.2.1.3 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-Mexico
6.3 Molecular Diagnostics--North America
6.3.1 Molecular Diagnostics--North America, by Geographies
6.3.1.1 Molecular Diagnostics--USA
6.3.1.2 Molecular Diagnostics--Canada
6.3.1.3 Molecular Diagnostics--Mexico
 

7 Molecular Diagnostics-North America, by Products
7.1 Split by Geography
7.4 Molecular Diagnostics-USA by Products
7.1 Molecular Diagnostics-Canada by Products
7.1 Molecular Diagnostics-Mexico by Products
7.2 Molecular Diagnostics Instruments-North America
7.2.1 Molecular Diagnostics Instruments-North America, by Companies
7.2.1.1 Molecular Diagnostics Instruments-Novartis AG-North America
7.2.2 Molecular Diagnostics Instruments-North America, by Geographies
7.2.2.1 Molecular Diagnostics Instruments-USA
7.2.2.2 Molecular Diagnostics Instruments-Canada
7.2.2.3 Molecular Diagnostics Instruments-Mexico
7.3 Molecular Diagnostics Reagents-North America
7.3.1 Molecular Diagnostics Reagents-North America, by Geographies
7.3.1.1 Molecular Diagnostics Reagents-USA
7.3.1.2 Molecular Diagnostics Reagents-Canada
7.3.1.3 Molecular Diagnostics Reagents-Mexico
7.4 Molecular Diagnostics Services-North America
7.4.1 Molecular Diagnostics Services-North America, by Geographies
7.4.1.1 Molecular Diagnostics Services-USA
7.4.1.2 Molecular Diagnostics Services-Canada
7.4.1.3 Molecular Diagnostics Services-Mexico
 

8 Molecular Diagnostics-North America, by Geographies
8.1 Molecular Diagnostics-USA
8.1.1 Molecular Diagnostics-USA, by Endusers
8.1.1.1 Molecular Diagnostics-USA-Hospitals
8.1.1.2 Molecular Diagnostics--USA
8.1.1.3 Molecular Diagnostics-USA-Medical & Diagnostic Laboratories
8.1.2 Molecular Diagnostics-USA, by Technologies
8.1.2.1 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-USA
8.1.2.2 Molecular Diagnostics--USA
8.1.3 Molecular Diagnostics-USA, by Applications
8.1.3.1 Molecular Diagnostics-Microbiology-USA
8.1.3.2 Molecular Diagnostics--USA
8.1.3.3 Molecular Diagnostics-Genetic Testing-USA
8.1.3.4 Molecular Diagnostics-USA-Hepatitis B
8.1.3.5 Molecular Diagnostics-USA-Hepatitis B
8.1.3.6 Molecular Diagnostics-USA-Hepatitis B
8.1.3.7 Molecular Diagnostics-USA-Hepatitis C
8.1.3.8 Molecular Diagnostics-USA-HIV/AIDS
8.1.3.9 Molecular Diagnostics-USA-Human Papillomavirus
8.1.3.10 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
8.1.3.11 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.1.3.12 Molecular Diagnostics-USA-Tuberculosis
8.1.3.13 Molecular Diagnostics-USA-Prostate Cancer
8.1.3.14 Molecular Diagnostics-USA-Breast Cancer
8.1.3.15 Molecular Diagnostics-USA-Colorectal Cancer
8.1.3.16 Molecular Diagnostics-USA-Hepatitis C
8.1.3.17 Molecular Diagnostics-USA-HIV/AIDS
8.1.3.18 Molecular Diagnostics-USA-Human Papillomavirus
8.1.3.19 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
8.1.3.20 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.1.3.21 Molecular Diagnostics-USA-Tuberculosis
8.1.3.22 Molecular Diagnostics-USA-Prostate Cancer
8.1.3.23 Molecular Diagnostics-USA-Breast Cancer
8.1.3.24 Molecular Diagnostics-USA-Colorectal Cancer
8.1.3.25 Molecular Diagnostics-USA-Hepatitis C
8.1.3.26 Molecular Diagnostics-USA-HIV/AIDS
8.1.3.27 Molecular Diagnostics-USA-Human Papillomavirus
8.1.3.28 Molecular Diagnostics-USA-Methicillin-resistant Staphylococcus aureus (MRSA)
8.1.3.29 Molecular Diagnostics-USA-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.1.3.30 Molecular Diagnostics-USA-Tuberculosis
8.1.3.31 Molecular Diagnostics-USA-Prostate Cancer
8.1.3.32 Molecular Diagnostics-USA-Breast Cancer
8.1.3.33 Molecular Diagnostics-USA-Colorectal Cancer
8.1.4 Molecular Diagnostics-USA, by Companies
8.1.4.1 Molecular Diagnostics-USA-Novartis AG
8.1.5 Molecular Diagnostics-USA, by Products
8.1.5.1 Molecular Diagnostics Instruments-USA
8.1.5.2 Molecular Diagnostics Reagents-USA
8.1.5.3 Molecular Diagnostics Services-USA
8.2 Molecular Diagnostics-Canada
8.2.1 Molecular Diagnostics-Canada, by Endusers
8.2.1.1 Molecular Diagnostics-Canada-Hospitals
8.2.1.2 Molecular Diagnostics-Canada-Medical & Diagnostic Laboratories
8.2.1.3 Molecular Diagnostics--Canada
8.2.2 Molecular Diagnostics-Canada, by Technologies
8.2.2.1 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-Canada
8.2.2.2 Molecular Diagnostics--Canada
8.2.3 Molecular Diagnostics-Canada, by Applications
8.2.3.1 Molecular Diagnostics-Microbiology-Canada
8.2.3.2 Molecular Diagnostics--Canada
8.2.3.3 Molecular Diagnostics-Genetic Testing-Canada
8.2.3.4 Molecular Diagnostics-Canada-Hepatitis B
8.2.3.5 Molecular Diagnostics-Canada-Hepatitis C
8.2.3.6 Molecular Diagnostics-Canada-HIV/AIDS
8.2.3.7 Molecular Diagnostics-Canada-Human Papillomavirus
8.2.3.8 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
8.2.3.9 Molecular Diagnostics-Canada-Hepatitis B
8.2.3.10 Molecular Diagnostics-Canada-Hepatitis C
8.2.3.11 Molecular Diagnostics-Canada-HIV/AIDS
8.2.3.12 Molecular Diagnostics-Canada-Human Papillomavirus
8.2.3.13 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
8.2.3.14 Molecular Diagnostics-Canada-Hepatitis B
8.2.3.15 Molecular Diagnostics-Canada-Hepatitis C
8.2.3.16 Molecular Diagnostics-Canada-HIV/AIDS
8.2.3.17 Molecular Diagnostics-Canada-Human Papillomavirus
8.2.3.18 Molecular Diagnostics-Canada-Methicillin-resistant Staphylococcus aureus (MRSA)
8.2.3.19 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.2.3.20 Molecular Diagnostics-Canada-Tuberculosis
8.2.3.21 Molecular Diagnostics-Canada-Prostate Cancer
8.2.3.22 Molecular Diagnostics-Canada-Breast Cancer
8.2.3.23 Molecular Diagnostics-Canada-Colorectal Cancer
8.2.3.24 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.2.3.25 Molecular Diagnostics-Canada-Tuberculosis
8.2.3.26 Molecular Diagnostics-Canada-Prostate Cancer
8.2.3.27 Molecular Diagnostics-Canada-Breast Cancer
8.2.3.28 Molecular Diagnostics-Canada-Colorectal Cancer
8.2.3.29 Molecular Diagnostics-Canada-Chlamydia trachomatis/ Neisseria gonorrhoeae
8.2.3.30 Molecular Diagnostics-Canada-Tuberculosis
8.2.3.31 Molecular Diagnostics-Canada-Prostate Cancer
8.2.3.32 Molecular Diagnostics-Canada-Breast Cancer
8.2.3.33 Molecular Diagnostics-Canada-Colorectal Cancer
8.2.4 Molecular Diagnostics-Canada, by Products
8.2.4.1 Molecular Diagnostics Instruments-Canada
8.2.4.2 Molecular Diagnostics Reagents-Canada
8.2.4.3 Molecular Diagnostics Services-Canada
8.3 Molecular Diagnostics-Mexico
8.3.1 Molecular Diagnostics-Mexico, by Technologies
8.3.1.1 Molecular Diagnostics--Mexico
8.3.1.2 Molecular Diagnostics-Transcription-mediated Amplification (TMA)-Mexico
8.3.2 Molecular Diagnostics-Mexico, by Products
8.3.2.1 Molecular Diagnostics Instruments-Mexico
8.3.2.2 Molecular Diagnostics Reagents-Mexico
8.3.2.3 Molecular Diagnostics Services-Mexico
 

9 Molecular Diagnostics-North America, by Companies
9.1 Competitive landscape
9.2 Split by Geography
9.5 Molecular Diagnostics-USA by Companies
9.1 Molecular Diagnostics-Canada by Companies
9.1 Molecular Diagnostics-Mexico by Companies
9.3 Molecular Diagnostics-North America-Novartis AG
9.3.1 Molecular Diagnostics-North America-Novartis AG, by Geographies
9.3.1.1 Molecular Diagnostics-USA-Novartis AG
9.3.2 Molecular Diagnostics-North America-Novartis AG, by Products
9.3.2.1 Molecular Diagnostics Instruments-Novartis AG-North America
9.4 Molecular Diagnostics-North America-Gen-Probe Incorporated
9.5 Molecular Diagnostics-North America-Novartis AG
9.5.1 Molecular Diagnostics-North America-Novartis AG, by Geographies
9.5.1.1 Molecular Diagnostics-USA-Novartis AG
9.5.2 Molecular Diagnostics-North America-Novartis AG, by Products
9.5.2.1 Molecular Diagnostics Instruments-Novartis AG-North America
9.6 Molecular Diagnostics-North America-Gen-Probe Incorporated
9.7 Molecular Diagnostics-North America-Novartis AG
9.7.1 Molecular Diagnostics-North America-Novartis AG, by Geographies
9.7.1.1 Molecular Diagnostics-USA-Novartis AG
9.7.2 Molecular Diagnostics-North America-Novartis AG, by Products
9.7.2.1 Molecular Diagnostics Instruments-Novartis AG-North America
9.8 Molecular Diagnostics-North America-Gen-Probe Incorporated
9.9 Molecular Diagnostics-North America-Abbott Diagnostics
9.10 Molecular Diagnostics-North America-Other Companies
9.11 Molecular Diagnostics-North America-Abbott Diagnostics
9.12 Molecular Diagnostics-North America-Other Companies
9.13 Molecular Diagnostics-North America-Abbott Diagnostics
9.14 Molecular Diagnostics-North America-Other Companies
9.15 Molecular Diagnostics-North America-Becton Dickinson & Company
9.16 Molecular Diagnostics-North America-Cepheid
9.17 Molecular Diagnostics-North America-BioMérieux
9.18 Molecular Diagnostics-North America-Siemens AG Healthcare

Please fill in the form below to receive a free copy of the Summary of this Report

* First Name :

* Last Name :

* Designation :

* Company :

* Email(Username) :

* Phone :

* Country :

-- Select Country -- India Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antigua Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia Herzegovina Botswana Brazil British Virgin Island Brunei Darussalam Bulgaria Burkina Faso Burundi Cote d'Ivoire Cambodia Cameroon Canada Cape Verde Cayman Isls Central African Republic Chad Chile China Colombia Comoros Congo Cook Island Costa Rica Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Faroe Islands Falkland Islands (Malvinas) Fiji Finl France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenl Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Holy See Honduras Hong Kong Special Administrative Hungary Iceland Indonesia Iran (Islamic Republic of Iran) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Special Administrative Region of China Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Micronesia Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherland Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Islands Northern Mariana Islands Norway Occupied Palestinian Territory Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Republic of Korea Republic of Moldova Romania Russian Federation Rwa Saint Helena Saint Kitts Nevis Saint Lucia Saint Pierre Miquelon Saint Vincent the Grenadines Samoa San Marino Sao Tome Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa Spain Sri Lanka Sudan Suriname Svalbard Jan Mayen Islands Swazil Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Thailand The former Yugoslav Republic of Macedonia Timor-Leste Togo Tokelau Tonga Trinidad Tobago Tunisia Turkey Turkmenistan Turks Caicos Isls Tuvalu Uga Ukraine United Arab Emirates United Kingdom United Republic of Tanzania United States United States Virgin Isls Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Wallis Futuna Isls Western Sahara Yemen Yugoslavia Zambia Zimbabwe

Comments :

Reports Interested in :North American Molecular Diagnostics Market

* Enter the text from the image to the text box :